New: NCI-funded clinical trial search
Mednet Logo

How do you approach management of bone marrow involvement in sarcoidosis?

Patient with mild cytopenias, but not requiring transfusions and no infection issues. Non-caseating granulomas on bone marrow biopsy.
5 Answers
Mednet Member
Rheumatology · Virginia Commonwealth University Health System
Answered on

This is an excellent question that certainly comes up frequently enough among sarcoidosis patients, and unfortunately with little guidance. Osseous involvement of sarcoidosis can include the bone marrow, leading to cytopenias. The levels of cytopenias can vary, and risk versus benefit should be taken into consideration when contemplating treatment. The risks of immunosuppressant therapy, of course, are worsening cytopenia, as many steroid-sparing agents have myelosuppressive side effects. Theref...

Join for free or sign in to see the full answer

Mednet Member
Rheumatology · Emory Health
Answered on

Monoclonal TNF inhibition would be an option as it is less likely to cause cytopenias and has shown some effectiveness in extrapulmonary Sarcoid. I have 2 patients who have anecdotally who have done well in the past.

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Rheumatology · Columbia University - New York Presbyterian Hospital
Answered on

Hematological abnormalities described in patients with sarcoidosis include leukopenia, anemia and thrombocytopenia. Pancytopenia is rarer but responds favorably corticosteroid therapy. A steroid sparing agent can be started once the pancytopenia has improved. TNF inhibitors are a great option when pancytopenia persist, and bone marrow suppression side effects with other steroid sparing agents (methotrexate, mycophenolate, azathioprine) is of concern.

Join for free or sign in to see the full answer

Mednet Member
Rheumatology · Jefferson Einstein Hospital
Answered on

Cytopenias due to sarcoidosis don’t always require treatment. Leukopenia and anemia are more common than thrombocytopenia. Isolated bone marrow involvement is also not very common and sometimes treatment indication/choice is guided by other potential organs involved. Agree with previous answers about favoring TNF-I if a treatment is required and the patient had a good response to steroids. Be also aware that anemia can be the result of chronic disease and not necessarily related to bone marrow i...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Rheumatology · U.S. Department of Veterans Affairs
Answered on

I would consider more cytopenic friendly meds: TNF, JAK over MMF or imuran. However, like most things in rheum it is the sarcoid causing the cytopenia then any TX that works is the goal. Would probably check counts q2 weeks as uptitration of more cytopenic agents and as counts improve q4 weeks x3 months.

Join for free or sign in to see the full answer